Clinical Trial Update: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

View source ↗

Summary

A non-interventional study sponsored by Novartis is evaluating the effectiveness and safety of ribociclib as adjuvant therapy for HR-positive, HER2-negative sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: RECRUITING